Former Chief Financial Officer · Eiger BioPharmaceuticals, Inc. (EIGR)

Sriram Ryali

A named executive officer of Eiger BioPharmaceuticals in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,291,946

Salary $500,000Stock awards $122,400

FY2021: $2,050,365

2nd of 4 named executive officers at Eiger BioPharmaceuticals by FY2022 total.

4 named officers on file for Eiger BioPharmaceuticals, FY2022

Sriram Ryali’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Eiger BioPharmaceuticals’s whole pay program stands against its peers

  • Eiger BioPharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on EIGR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A).

Free

Get Sriram Ryali’s full pay file as a PDF — free

More than this page: up to 10 years of Sriram’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Sriram Ryali compensation by year

Eiger BioPharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Eiger BioPharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$448,062$500,000
Bonus$0$0
Stock awards$162,338$122,400
Option awards$1,225,090$455,913
Non-equity incentive$202,100$200,000
Pension and deferred compensation$0$0
All other$12,775$13,633
Total$2,050,365$1,291,946

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Eiger BioPharmaceuticals, Inc. DEF 14A filed April 26, 2023, accession 0001140361-23-020609, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Eiger BioPharmaceuticals, Inc. filed document, accession 0001140361-23-020609. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

$2.1M
$1.3M
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU30,000$35,400—
RSU24,000$28,320—
RSU10,833$12,783—
Option4,608—$8.49
Option20,313—$5.60
Option40,118—$9.99
Option14,726—$9.99
Option107,249—$5.10
Option47,955—$8.49
Option15,834—$8.15
Option8,939—$5.10

Per the Outstanding Equity Awards at Fiscal Year-End table in Eiger BioPharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Eiger BioPharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
David CoryFormer President and Chief Executive Officer$3,683,861
Sriram Ryali · this pageFormer Chief Financial Officer$1,291,946
Eldon MayerExecutive Vice President and Chief Commercial Officer$981,007
David ApelianInterim Chief Executive Officer$204,386

The full Eiger BioPharmaceuticals compensation record

free company brief

This page is one person within Eiger BioPharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Eiger BioPharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Sriram Ryali's compensation dossier · One-time report. No refunds.